Haemonetics TEG® 6s

The design and usability of the TEG® 6swas informed through deep user insights, Voice of Customer research and market knowledge. Compact and minimalist, the instrument's form is designed to enable it to fit in space-restricted laboratories, or manually transported and placed amongst a multitude of equipment in an operating theatre. Usability is at the core of the design, which is dominated by a touchscreen/user-interface and cartridge slot (which illuminates when ready for use). A non-slip carry-handle has been integrated into the overall design.

The TEG® 6s provides a complete picture of haemostasis, offering insights into different aspects of coagulation, while eliminating the need for multiple tests. The simplified process and near-patient testing allows clinicians to drive personalized, clinically and economically sound treatment and monitoring decisions. The TEG® system enables both coagulation and the effects of antiplatelet therapy to be assessed using one device. The TEG® 6s analyzer is a connected device able to network via a user interface to TEG® Manager™. Data from multiple devices can be centralized, allowing remote access to any connected analyzer with the ability to view active and historical test results

Designed for use in a controlled clinical environment, the TEG® 6s offers significant safety advantages over competitor products through features such as simple, single use cartridges, test preparation without complex mixing and pipetting, and small blood volumes per test which are introduced by a disposable pipette. Usage of the device is guided by an intuitive user interface. No sharps are required for device operation. The TEG® 6s was developed to comply with a number of safety, EMC and RoHS compliance standards including but not limited to: IEC61010, IEC61326, RoHS Directive 2002/95/EC, and ISO 15223

The TEG® 6s complies with RoHS (Reduction of Hazardous Substances) Directive 2002/95/EC. As an IVD medical device which likely to be regarded as infective prior to end of life, it is exempt from the Directive 2012/19/EU on Waste Electrical and Electronic Equipment (WEEE)

The TEG® 6s has been designed for reliable, consistent, repeatable operation. It features numerous QC functions including automated power on self-tests, prior-to-run tests, and will identify samples that are outside reference ranges. The test methodology is significantly less susceptible to environmental issues, in particular vibration, which is particularly important given the haemostasis analysis is determined through resonance.

The TEG® 6s offers point of care testing without having to perform complicated test procedures. A complete picture of haemostasis is achieved with one test containing up to four assays. The TEG® system enables both coagulation and the effects of antiplatelet therapy to be assessed using one device. Therefore, the need for a specific platelet assessment device may be removed.

The TEG® 6s features many breakthrough technologies, in particular those centered around the resonance and sensing algorithm, which is a major improvement over mechanical measurement of blood haemostasis. This is achieved via complex algorithms that measure vibration across time. Further innovations are realized through the removal of complex blood sample preparation steps. The innovative all-in-one cartridge means that quality test results can be delivered without complicated manual processing, which in the past could take up to 15 minutes.